World Pharma News

Syndicate content
World Pharma News - one of the world's leading web-based pharmaceutical news publications - is committed to providing and disseminating the most prominent pharmaceutical news and achievements
Updated: 30 min 49 sec ago

BioNTech's statement on patent infringement lawsuit filed by Moderna

Mon, 08/29/2022 - 10:00
BioNTech SE (Nasdaq: BNTX, "BioNTech") published an official statment: "BioNTech is aware of reports that Moderna has sued Pfizer and BioNTech, alleging that COMIRNATY® infringes certain Moderna patents. BioNTech's work is original, and we will vigorously defend against all allegations of patent infringement.

Moderna sues Pfizer and BioNTech for infringing patents central to Modernas innovative mRNA technology platform

Fri, 08/26/2022 - 10:00
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today is filing patent infringement lawsuits against Pfizer and BioNTech in the United States District Court for the District of Massachusetts and the Regional Court of Düsseldorf in Germany.

Novartis announces intention to separate Sandoz business to create a standalone company by way of a 100% spin-off

Thu, 08/25/2022 - 10:00
Novartis today announced its intention to separate Sandoz, its generics and biosimilars division into a new publicly traded standalone company, by way of a 100% spin-off.

The spin-off aims to maximize shareholder value by creating the #1 European generics company(1) and a global leader in biosimilars, allowing Novartis shareholders to participate fully in the potential future upside for both Sandoz and Novartis Innovative Medicines.

New generation of corona vaccine shows promising results

Wed, 08/24/2022 - 10:00
Researchers at Karolinska Institutet in Sweden are developing a coronavirus vaccine designed to be less sensitive to mutations and equipped for future strains. The vaccine showed promising results in mice in a newly published study in EMBO Molecular Medicine, and the researchers now hope to be able to take it to safety studies on humans.

Study first to link weed killer Roundup® to convulsions in animals

Tue, 08/23/2022 - 10:00
A recent report by the United States Centers for Disease Control and Prevention found more than 80 percent of urine samples from children and adults in the U.S. contained the herbicide glyphosate. A study by Florida Atlantic University and Nova Southeastern University takes this research one step further and is the first to link the use of the herbicide Roundup®, a widely used weed killer, to convulsions in animals.

Pfizer and BioNTech submit application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine

Mon, 08/22/2022 - 10:00
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) of a booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years of age and older.

Metformin drastically reduces COVID hospitalization

Fri, 08/19/2022 - 10:00
The widely available diabetes drug metformin reduced serious outcomes by more than half if started within 4 days of COVID symptoms in a large, randomized, double blind controlled trial, the University of Minnesota announced today. The results were published Aug. 18 in the New England Journal of Medicine.

Bayer supports demining in Ukraine with donation to non-profit "Fondation suisse de déminage"

Thu, 08/18/2022 - 10:00
Bayer supports the humanitarian non-profit organization "Fondation suisse de déminage" (FSD) in their mission to demine land that was contaminated by mines and unexploded devices since the onset of the war in Ukraine. A donation of 825,000 euros will be dedicated to purchasing a large-size mechanical mine clearance machine.

Powerful new antibody neutralizes all known SARS-CoV-2 variants

Wed, 08/17/2022 - 10:00
As SARS-CoV-2 has evolved and mutated, therapeutic antibodies that worked early in the pandemic have become less effective, and newer variants, especially Omicron, have developed ways to evade the antibodies we make in response to vaccines. A new, broadly neutralizing antibody developed at Boston Children's Hospital could potentially improve our ability to defend against future variants.

Scientists develop gel made from spider silk proteins for biomedical applications

Tue, 08/16/2022 - 10:00
Researchers at Karolinska Institutet in Sweden and the Swedish University of Agricultural Sciences have discovered that spider silk proteins can be fused to biologically active proteins and be converted into a gel at body temperature. One of the goals is to develop an injectable protein solution that forms a gel inside the body, which could be used in tissue engineering and for drug release, but also make gels that can streamline chemical processes where enzymes are used.

Pfizer announces positive top-line results from Phase 3 study of 20-valent pneumococcal conjugate vaccine in infants

Mon, 08/15/2022 - 09:00
Pfizer Inc. (NYSE:PFE) announced positive top-line results from its pivotal U.S. Phase 3 study (NCT04382326) in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes contained in the vaccine for the pediatric population.

Roche announces U.S. FDA approval of Xofluza to treat influenza in children aged five years and older

Fri, 08/12/2022 - 10:00
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza® (baloxavir marboxil) for the treatment of acute uncomplicated influenza in otherwise healthy children aged five to less than 12 years of age who have been symptomatic for no more than 48 hours.

New method of nasal vaccine delivery could lead to better vaccines for HIV and COVID-19

Thu, 08/11/2022 - 10:00
A University of Minnesota assistant professor is part of a team that has developed a new way to effectively deliver vaccines through mucosal tissues in the nose that could lead to better protection against pathogens like human immunodeficiency virus (HIV) and SARS-CoV-2, the virus that causes COVID-19.

Research identifies, exploits vulnerability in certain high-risk cancers

Wed, 08/10/2022 - 10:00
In a study recently published in Cancer Research, a journal of the American Association for Cancer Research, a team of researchers led by C. Patrick Reynolds, M.D., Ph.D., director for the Texas Tech University Health Sciences Center (TTUHSC) School of Medicine Cancer Center, sought to expand upon his lab's previous research that showed ALT tumors identified by a biomarker known as C-circles share a common biology that confers vulnerabilities to be exploited for cancer therapy.

Scientists create long-acting injectable drug delivery system for tuberculosis

Tue, 08/09/2022 - 10:00
In 2020, more than 1.5 million people around the world died of tuberculosis, marking the first time in more than a decade that annual TB deaths had increased and demonstrating the global need for better access to treatments. To address that problem, scientists at the UNC School of Medicine, the UNC Institute for Global Health and Infectious Diseases, and the International Center for the Advancement of Translational Science developed a long-acting injectable formulation of the anti-TB drug rifabutin.

Pfizer to acquire Global Blood Therapeutics for $5.4 billion to enhance presence in rare hematology

Mon, 08/08/2022 - 10:00
Pfizer Inc. (NYSE: PFE) and Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the companies have entered into a definitive agreement under which Pfizer will acquire GBT, a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease (SCD).

Treating cancer by sticking cells in place

Fri, 08/05/2022 - 10:00
Future treatments for advanced cancer could work by sticking cancer cells in place and preventing their spread around the body. A new study by researchers at the University of California, Davis, and the University of Washington shows how an antibody strengthens bonds between cells. The work is published Aug. 3 in Proceedings of the National Academy of Sciences.

Roche's subcutaneous formulation of Tecentriq demonstrates positive Phase III results

Thu, 08/04/2022 - 10:00
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the Phase III IMscin001 study evaluating a subcutaneous formulation of Tecentriq® (atezolizumab) met its co-primary endpoints. The study showed non-inferior levels of Tecentriq in the blood (pharmacokinetics), when injected subcutaneously, compared with intravenous (IV) infusion, in cancer immunotherapy-naïve patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) for whom prior platinum therapy has failed.

Vitamin K prevents cell death: a new function for a long-known molecule

Wed, 08/03/2022 - 10:00
Vitamin K is well-known for its blood clotting and bone building properties but today a new study published in Nature reports on a novel function for vitamin K.

The researchers discovered that the fully reduced form of vitamin K acts as an antioxidant efficiently inhibiting ferroptotic cell death. Ferroptosis is a natural form of cell death in which cellular iron plays an important role and which is characterized by the oxidative destruction of cellular membranes.

Bayer Consumer Health leaders propose new principles for science-led self-care

Tue, 08/02/2022 - 10:00
Bayer has published a new paper, Science-Led Self-Care: Principles for Best Practice, that sets out five key Principles that should underpin all self-care products improving personal health and wellness. The paper is intended to spark a conversation within the industry and its key stakeholders around the need to promote science-led self-care for the benefit of consumers.